Abstract:The most aggressive types of ovarian cancer is high-grade serous ovarian cancer (HGSOC), and the 5-year survival is less than 20%. Relapsed HGSOC patients often have enrichment of cancer stem cells (CSCs) with enhanced pro-survival and self-renewal capacity, suggesting a potential vulnerable population for effective targeted therapies with less toxicity. APOBEC3 proteins are a family of primate-specific DNA deaminases that catalyze cytidine to uracil (C-to-U) on single-strand DNA thereby introducing C-to-T/G point mutations. This important DNA modification is abundant in a wide array of cancer types including HGSOCs. However, the prevalence and significance of A3-induced DNA deamination in HGSOC CSC is currently unknown. We recently discovered that CSCs maintain a low A3-induced mutation burden. Using patient-sample derived spheroid culture and HGSOC cell lines, we found A3B was the only A3 members differentially expressed between CSC and non-CSC and the expression was significantly reduced in CSCs. In addition, inhibition of A3B leads to elevated frequency of CSCs and enhanced expression of the stemness factors. Important, our data suggest that DNA deaminase activity of A3B leads to induction of DNA damage thereby sensitizing HGSOC CSCs to PARPi. These novel insights suggest that DNA deamination plays a fundamental role in CSC biology and also raises the possibility that A3B activation may sensitize HGSOC CSCs to PARPi by promoting DNA damages. Citation Format: Jane isquith, Jessica Pham, Robert Phavong, Maria Rivera, Kathleen Fisch, Catriona Jamieson, Michael McHale, Ramez Eskander, Qingfei Jiang. DNA deaminase APOBEC3B regulates theresponse to PARP inhibitors of epithelial ovarian cancer stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 890.

The Poly(adp-Ribose) Polymerase-1 Inhibitor 3-Aminobenzamide Suppresses Cell Growth and Migration, Enhancing Suppressive Effects of Cisplatin in Osteosarcoma Cells.

Inhibitory Effects of PARP-1 Inhibitor on Growth of Human Osteosarcoma Cells.

Suppression of Osteosarcoma Cells Growth by 3-Aminobenzamide Combined with Cisplatin

Potential Biomarkers Of Poly (Adp-Ribose) Polymerase Inhibitors For Cancer Therapy

Checkpoint Kinase Inhibitor AZD7762 Enhance Cisplatin-Induced Apoptosis in Osteosarcoma Cells.

Antisense C - Myc Sensitizes Osteosarcoma Cells to Cisplatin- Induced Apoptosis

Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin.

Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer.

Breaking the Iron Homeostasis: A “trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Bio-inspired Cisplatin Nanocarriers for Osteosarcoma Treatment.

Olaparib Synergizes with Arsenic Trioxide by Promoting Apoptosis and Ferroptosis in Platinum-Resistant Ovarian Cancer.

Synergetic Effect of Poly (Adp-Ribosyl) Polymerase (PARP) Inhibitor and Cisplatin on Ovarian Cancer

The Inhibition and Treatment of Breast Cancer with Poly (Adp-Ribose) Polymerase (PARP-1) Inhibitors.

The discovery of a potent PARP1 inhibitor Senaparib

Design, synthesis, and biological evaluation of a series of benzofuran[3,2-d]pyrimidine-4(3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors

Berberine and Cisplatin Exhibit Synergistic Anticancer Effects on Osteosarcoma MG-63 Cells by Inhibiting the MAPK Pathway

Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property

Olaparib Increases Chemosensitivity by Upregulating Mir-125A-3p in Ovarian Cancer Cells

Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines

Abstract 890: DNA deaminase APOBEC3B regulates theresponse to PARP inhibitors of epithelial ovarian cancer stem cells